Informed Consent in Clinical Trials: What CRCs Must Know for Certification

Informed consent is one of the most heavily tested topics on both the ACRP and SOCRA certification exams — and for good reason. It's the ethical cornerstone of clinical research, the process through which participants exercise their autonomy, and the area where CRCs often have the most direct, hands-on responsibility.

If you're preparing for your certification exam, you need to know informed consent inside and out. Here's everything that matters.

Informed Consent Is a Process, Not a Form

This is the single most important concept to understand — and one of the most common exam traps. Informed consent is not the act of signing a document. It's an ongoing process of communication between the research team and the participant that begins before enrollment and continues throughout the study.

The signed consent form is documentation that the process occurred. But the form alone doesn't constitute valid consent. If a participant signs a form without genuinely understanding the study, the consent is not truly informed — regardless of the signature.

The 8 Required Elements of Informed Consent

Under ICH-GCP and U.S. federal regulations (21 CFR 50.25), the informed consent document must include these essential elements. You should be able to recognize and explain each one:

1. Statement that the study involves research — including the purpose, expected duration, description of procedures, and identification of any experimental components.
2. Description of reasonably foreseeable risks or discomforts — including both known risks and those that are possible but not yet confirmed.
3. Description of potential benefits — to the participant or to others. Note that benefits should not be overstated, and compensation is NOT a benefit of participation.
4. Disclosure of alternative treatments or procedures — participants must know what options exist outside the study.
5. Description of confidentiality protections — how data and records will be protected, and who may have access (including regulatory authorities).
6. Explanation of compensation and medical treatment — if injury occurs, what compensation and treatment is available and where to find more information.
7. Contact information — for questions about the research, participants' rights, and research-related injuries.
8. Statement that participation is voluntary — and that withdrawal at any time will not result in penalty or loss of benefits.

When Re-Consent Is Required

The initial consent process is just the beginning. Participants must be re-consented when there are significant changes that could affect their willingness to continue. Common triggers include:

• Protocol amendments that change the risk/benefit profile
• New safety information that emerges during the trial
• Changes to study procedures that affect the participant's experience
• Updates to the Investigator's Brochure with new safety data

The IRB/IEC must approve the revised consent document before it's used. Participants who are already enrolled must be re-consented with the updated information — their original consent doesn't automatically cover new risks or changes.

Vulnerable Populations: Special Protections

Certain populations require additional safeguards during the consent process. These include:

Children and minors: Require both parental/guardian permission AND the child's assent (agreement) when they're old enough to understand. The updated E6(R3) guidelines now explicitly require IRBs to review assent materials for trials involving minors.

Cognitively impaired individuals: A legally authorized representative (LAR) may provide consent, but the participant's assent should still be sought to the extent possible.

Emergency research: Under specific FDA regulations (21 CFR 50.24), informed consent requirements can be waived in emergency situations where there's no time to obtain consent and no alternatives are available. This exception has strict requirements including community consultation and public disclosure.

Economically or educationally disadvantaged: The consent process should account for literacy levels, language barriers, and the potential for undue influence. Compensation that's appropriate for one population may be coercive for another.

Electronic Consent (eConsent)

With the rise of decentralized trials, electronic informed consent is increasingly common. E6(R3) provides additional clarity on eConsent, affirming that it's acceptable when properly implemented. Key considerations include:

• The eConsent platform must ensure the participant can review all required information
• The participant must have the opportunity to ask questions (which may be done via video call or phone)
• Electronic signatures must comply with applicable regulations (e.g., 21 CFR Part 11 in the U.S.)
• The system must produce a durable record of the consent process

Expect certification exams to include more questions about eConsent as the practice becomes standard across the industry.

Common Exam Scenarios

Scenario: A participant asks, "What happens if I decide to stop the study?" The correct answer must include: participation is voluntary, withdrawal can occur at any time, and no penalty or loss of benefits will result. However, the research team may explain what happens clinically upon withdrawal (e.g., follow-up safety assessments).

Scenario: A new safety risk is identified during an ongoing trial. The correct response: notify the IRB, revise the consent document, obtain IRB approval of the revision, and re-consent all currently enrolled participants.

Scenario: A CRC notices that a participant signed the consent form but appears not to understand the study procedures. The correct action: stop and re-explain. A signature without understanding is not valid informed consent. The CRC should document the additional discussion.

The Ethical Foundation: Why This Matters

Informed consent isn't just a regulatory requirement — it's rooted in the fundamental ethical principles of clinical research. The Belmont Report established respect for persons, beneficence, and justice as the foundation of human subjects protection. Informed consent is the practical expression of respect for persons — recognizing that every participant has the right to make autonomous decisions about their own body and health.

As a CRC, you're often the person sitting across the table from a participant during the consent conversation. You're not just reviewing a form — you're upholding one of the most important ethical principles in medicine.